Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1991-2-14
|
| pubmed:abstractText |
One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of standard continuation therapy. The dose and sequence of MTX/Ara-C administration were based on a preclinical model that demonstrated synergism between MTX and Ara-C. Poor-risk patients (n = 49) were assigned to "up-front" therapy, in which the MTX/Ara-C courses were administered during the initial 15 weeks of remission. Standard-risk patients (n = 57) were assigned to "spread-out" therapy, in which the MTX/Ara-C courses were interspersed at 12-week intervals within continuation treatment. Toxicity after intermediate-dose MTX/Ara-C, principally neutropenia and fever, was judged significant but manageable. Unexpectedly, the incidence of fever and neutropenia less than 500/mm3 was greater after "spread-out" therapy (38%) than after "up-front" therapy (6%). At 4 years, the Kaplan-Meier estimate of event-free survival (EFS) is 71% (+/- 7%) for standard-risk patients and 53% (+/- 8%) for poor-risk patients. The results of this pilot study support the use of intermediate-dose MTX/Ara-C in additional studies.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
67
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
550-6
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:1985748-Adolescent,
pubmed-meshheading:1985748-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1985748-Child,
pubmed-meshheading:1985748-Child, Preschool,
pubmed-meshheading:1985748-Cytarabine,
pubmed-meshheading:1985748-Drug Administration Schedule,
pubmed-meshheading:1985748-Drug-Induced Liver Injury,
pubmed-meshheading:1985748-Female,
pubmed-meshheading:1985748-Fever,
pubmed-meshheading:1985748-Humans,
pubmed-meshheading:1985748-Infant,
pubmed-meshheading:1985748-Infection,
pubmed-meshheading:1985748-Length of Stay,
pubmed-meshheading:1985748-Leukocyte Count,
pubmed-meshheading:1985748-Male,
pubmed-meshheading:1985748-Methotrexate,
pubmed-meshheading:1985748-Neutropenia,
pubmed-meshheading:1985748-Pilot Projects,
pubmed-meshheading:1985748-Platelet Count,
pubmed-meshheading:1985748-Pneumonia,
pubmed-meshheading:1985748-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:1985748-Recurrence,
pubmed-meshheading:1985748-Remission Induction,
pubmed-meshheading:1985748-Survival Rate
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
|
| pubmed:affiliation |
Division of Pediatrics, City of Hope National Medical Center, Duarte, California.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|